Sorrento To Start Testing Non-Opioid Candidate In Osteoarthritis-Related Knee Pain

The FDA has signed off Sorrento Therapeutics Inc's SRNE Phase 2 study of Resiniferatoxin (RTX) for moderate-to-severe osteoarthritis of the knee pain (OAK).
The Phase 2 trial, a multi-center, double-blind, placebo- and active-controlled study, will assess the efficacy and safety of several dose groups of RTX to manage pain in patients.
Sorrento has decided to include an active comparator (injectable corticosteroid) in the current trial protocol.
This Phase 2 study follows the analysis of the significant observations from the Phase 1b trial results.
Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose-limiting toxicity at any doses tested up to 30 ug.
Phase 1b data demonstrated significant efficacy supporting RTX as an ideal candidate for long-term control of refractory OA pain: effective pain relief observed in patients with advanced OA disease and sustained pain relief last beyond six months.
Price Action: SRNE shares are down 0.11% at $9.51 during the premarket session on the last check Wednesday.